Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.

Brendon L Neuen Megumi Oshima Vlado Perkovic Rajiv Agarwal Clare Arnott George L BakrisChristopher P CannonDavid M CharytanRobert EdwardsJose Luis Gorriz Teruel Meg J JardineAdeera LevinBruce C Neal Luca De Nicola Carol A Pollock Norman Rosenthal David Collins WheelerKenneth W MahaffeyHiddo J L Heerspink

Published in: European heart journal (2021)

Among patients treated with renin-angiotensin-aldosterone system inhibitors, SGLT2 inhibition with canagliflozin may reduce the risk of hyperkalaemia in people with T2DM and CKD without increasing the risk of hypokalaemia.

Keyphrases

chronic kidney disease
angiotensin converting enzyme
angiotensin ii
end stage renal disease
glycemic control
type diabetes
cardiovascular disease
study protocol
phase iii
clinical trial
phase ii
randomized controlled trial
adipose tissue
weight loss
open label